Project Updates

EyePoint Pharmaceuticals

 Credit: Gorman Richardson Lewis Architects.

Location: Northbridge, Massachusetts, US
Project type: Manufacturing facility
Announced: January 2024
Expected Completion: H2 2024

EyePoint Pharmaceuticals, a US-based pharmaceutical company, will expand its laboratory and manufacturing capabilities with the construction of a new, custom-built commercial manufacturing facility. The facility will support the global production of the company’s programmes.

AstraZeneca

 Credit: Business Wire.

Location: Rockville, Maryland, US
Project type: Manufacturing facility
Announced: February 2024
Estimated Investment: $300m

AstraZeneca, a biopharmaceutical company based in the UK, will build an advanced manufacturing facility in Rockville, Maryland, US, to launch its life-saving cell therapy platforms in the US, which are essential for critical cancer trials and future commercial supply.

Regenxbio

Credit: REGENXBIO

Location: Rockville, Maryland
Project type:  R&D facility
Investment: $65m
Opened: June 2022

Regenxbio built a research and development facility, which it calls the Manufacturing Innovation Center, in Montgomery County in Rockville, Maryland, US. The facility will provide the company with complete control over the entire gene therapy manufacturing process in Montgomery County.

Go to article: Home | What’s next for AAV gene therapies in 2024?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: phasetwoGo to article: Avenga Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: Zenatek Company InsightGo to article: Simtra BioPharma SolutionsGo to article: In DepthGo to article: What’s Next for AAV Gene Therapies in 2024?Go to article: Traceability technologies tighten supply chain fakeryGo to article: Switching sales: Investigating the financial impacts of FDA’s priority vouchersGo to article: Is HIV-TB coinfection treatment entering a new frontier?Go to article: Patient organisations need to tackle transparency Go to article: AD/PD 2024: Eli Lilly’s donanemab hit with FDA delay Go to article: Q&A: Increasing awareness around digital therapeutics key to realising full potentialGo to article: Sponsored SupplementsGo to article: Lactalis IngredientsGo to article: BEA TechnologiesGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue